Clot microstructure as a marker of thrombogenicity in cancer
Research type
Research Study
Full title
FRACTAL DIMENSION (DF) AS A BIOMARKER OF THROMBOGENICITY IN CANCER ASSOCIATED THROMBOSIS.
IRAS ID
266720
Contact name
Phillip Adrian Evans
Contact email
Sponsor organisation
Swansea Bay University Health Board
Duration of Study in the UK
1 years, 11 months, 30 days
Research summary
Research Summary
The work will be carried out at Morriston Hospital (Swansea Bay University Health Board).The study will build on our previous work which demonstrated that a new blood test developed at Swansea was able to identify differences in the blood of lung cancer compared to people without lung cancer. The test also showed that patients with more advanced lung cancer had the biggest change in their blood. In this new study we aim to explore this further. We aim to identify which lung cancer patients are at the highest risk of developing blood clots, a common problem in this group of patients. We aim to recruit 120 lung cancer patients. The results of the proposed study would be invaluable in predicting the risk some patients are at of developing clots which have a detrimental effect on the patient. The goal of the research is the development of a pragmatic risk assessment tool which may then be used to personalize and target treatment to benefit those most at risk, whilst decreasing the complications observed in patients who are not at the highest risk of developing clots.Summary of Results
The study was terminated early as it was not possible to recruit due to Covid restrictions, due to potential risk of transmission to a particularly vulnerable group of patients.REC name
Wales REC 4
REC reference
19/WA/0182
Date of REC Opinion
10 Jul 2019
REC opinion
Further Information Favourable Opinion